News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘BasicResearch’ clear

  • Dana-Farber investigators led a phase 1 trial in which a new oral targeted drug, idelalisib, (GS-1101), showed the potential to stave off the need for additional treatments for relapsed or treatment-resistant CLL.

Tags: BasicResearch, Leukemia

  • A type of low-grade but sometimes lethal brain tumor in children has been found to contain an unusual mutation that may help to classify, diagnose and guide the treatment of the tumors.

Tags: BasicResearch, ChildhoodCancer, BrainTumors

  • Dana-Farber researchers detail how low doses of interleukin-2 (IL-2) can alleviate chronic graft-versus-host disease (GVHD) and possibly lead to better treatment for other immune disorders.

Tags: BasicResearch, GraftVersusHost

  • An irregularity within many neuroblastoma cells may indicate whether the tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.

Tags: BasicResearch, ChildhoodCancer

  • Dana-Farber scientists find when given together, two orally available experimental drugs – sapacitabine and seliciclib – worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers.

Tags: BasicResearch, BreastCancer, OvarianCancer, PancreaticCancer, GynecologicCancers

  • Dana-Farber researchers find blood test can provide fuller picture of cancer mutations in gastrointestinal stromal tumors than biopsy.

Tags: BasicResearch

  • Dana-Farber researchers find novel antibody-guided drug achieves responses in platinum drug-resistant ovarian cancer.

Tags: BasicResearch, OvarianCancer, GynecologicCancers

  • Dana-Farber scientists found that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.

Tags: BasicResearch, PancreaticCancer, TargetedTherapy

  • A study by scientists at Dana-Farber Cancer Institute, the Broad Institute, and other research centers, may offer clues to why rates of esophageal adenocarcinomas (EACs) have risen so sharply. The findings, in Nature Genetics, point to an array of abnormal genes and proteins that may be lynchpins of EAC cell growth and therefore serve as targets for new therapies.

Tags: BasicResearch, Genomics, TargetedTherapy

  • Dana-Farber scientists have linked genetic variants to the regulation of genes involved in breast cancer, including four genes not previously implicated in breast cancer, shedding new insights into the biology of breast cancer.

Tags: BasicResearch, BreastCancer, Genomics

Showing 1-10 of 115 items